UAE RUO Immunoassay Market Size, Share, Opportunities, And Trends By Product Type (Immunoassay Kits, Immunoassay Reagents, Microplate Reader, Microplates, Analyzers (Automated Analyzers, Non-Automated Analyzers), Microplate Washers, Others), By Sample Type (Plasma, Blood Serum, Urine, Saliva, Cell or Tissue Culture Medium, Others), By Application (Oncology, Blood Screening and Toxicology, Infectious Disease, Cardiology, Allergy Diagnostic, Rare and Emerging Condition Diagnostic, Others), By End-User (Research and Academic Laboratories, Pharmaceutical and Biotechnology Companies), And By State - Forecasts From 2025 To 2030

UAE RUO Immunoassay Market Size:

UAE RUO immunoassay market is expected to grow at a CAGR of 14.56% from 2025 to 2030.

UAE RUO Immunoassay Market Trends:

The UAE is noticing a rise in cardiovascular disease (CVD) prevalence and requires prompt addressing to target the risk factors involved like high cholesterol levels, high blood pressure, and obesity. Researchers are focused on developing techniques for early diagnosis and detection of these risk factors, RUO immunoassays can assist in biomarker profiling, which is linked to obesity and CVD subtypes, this could boost expansion in RUO immunoassay demand in the United Arab Emirates in the years ahead.

The World Obesity Federation predicts a significant increase in overweight or obesity among young people aged 5-19 years in UAE, from 38% (470,000 children) in 2020 to 49% (680,000 children) by 2035. This could result in 66,127 children having high blood pressure, 24,815 having hyperglycemia, and 69,640 having low HDL cholesterol caused as a result of obesity. Additionally, the 2022 World Obesity Atlas report predicts a 50% prevalence of obesity among women by 2030 and 37% in men in the UAE. As per WHO data of May 2021, about 4,800 UAE residents die annually from non-communicable diseases, accounting for 55% of all deaths, with CVD accounting for 34% of all deaths, causing the most deaths annually.

The country is prioritizing translational research in the healthcare sector to bridge the gap between scientific discoveries and clinical applications which will require validating biomarkers, studying disease mechanisms, and developing therapeutic interventions, and RUO immunoassay is a vital and significant part of this. In March 2024, Nobel laureate James Allison who is known for groundbreaking work on revolutionized cancer immunotherapy, expressed optimism about the UAE's healthcare system for cancer patients, highlighting the infrastructure being built in Abu Dhabi and the UAE for drug development and new cancer treatments.

In March 2023, NIH published an article on the rise in priorities for cardiovascular health research in the United Arab Emirates. Stroke is the second leading cause of disability in the UAE, affecting 8,000 to 10,000 patients annually, equivalent to one stroke every hour, according to data published by Burjeel Hospital in July 2022.

In 2022, Saudi Arabia launched the first phase of strategy development, revealing the roadmap for Saudi Genome Program (SGP) 2.0. The goal is to establish the Kingdom as a global leader in genomics, focusing on collaborations on genetic diseases, leading in the MENA region, and ensuring genomics plays a crucial role in providing high-quality healthcare to all citizens. This vision aims to revolutionize the future of healthcare. Investing in Abu Dhabi's Life-Science Sector data 2022 reveals a regulatory framework for international collaborations with top research centers and leading health institutions, over 72 authorized facilities to conduct human subject research, more than 51% priority research, and over 120 research reviewed by the IRB.

UAE RUO Immunoassay Market Scope:

Report Metric	Details
UAE RUO Immunoassay Market Size in 2025	US$8.525 billion
UAE RUO Immunoassay Market Size in 2030	US$11.021 billion
Growth Rate	CAGR of 14.56%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Product Type Sample Type Application End-User State
Geographical Segmentation	Abu Dhabi, Dubai, Sharjah, Others
List of Major Companies in the UAE RUO Immunoassay Market	F. Hoffmann-La Roche Ltd Merck KGaA Danaher Corporation Quanterix Corporation Thermo Fisher Scientific Inc.
Customization Scope	Free report customization with purchase

 

UAE RUO Immunoassay Market Segmentations:

By Product Type

• Immunoassay Kits
  • Enzyme-Linked Immunosorbent Assay (ELISA) Kits
    • Conventional
    • Manual
  • Radioimmunoassay (RIA Kits)
    • Conventional
    • Manual
  • Chemiluminescent Immunoassay (CLIA) Kits
• Immunoassay Reagents
• Microplate Reader
• Microplates
• Analyzers
  • Automated Analyzers
  • Non-Automated Analyzers
• Microplate Washers
• Others

By Sample Type

• Plasma
• Blood Serum
• Urine
• Saliva
• Cell or Tissue Culture Medium
• Others

By Application

• Oncology
• Blood Screening and Toxicology
• Infectious Disease
• Cardiology
• Allergy Diagnostic
• Rare and Emerging Condition Diagnostic
• Others

By End-User

• Research and Academic Laboratories
• Pharmaceutical and Biotechnology Companies

By Region

• Abu Dabi
• Dubai
• Sharjah
• Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

4.1. Product Pipeline

5. UAE RUO IMMUNOASSAY MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Immunoassay Kits

5.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Kits

5.2.1.1. Conventional 

5.2.1.2. Manual

5.2.2. Radioimmunoassay (RIA Kits)

5.2.2.1. Conventional 

5.2.2.2. Manual

5.2.3. Chemiluminescent Immunoassay (CLIA) Kits

5.3. Immunoassay Reagents

5.4. Microplate Reader

5.5. Microplates

5.6. Analyzers

5.6.1. Automated Analyzers

5.6.2. Non-Automated Analyzers

5.7. Microplate Washers

5.8. Others

6. UAE RUO IMMUNOASSAY MARKET BY SAMPLE TYPE

6.1. Introduction

6.2. Plasma 

6.3. Blood Serum

6.4. Urine

6.5. Saliva

6.6. Cell or Tissue Culture Medium

6.7. Others

7. UAE RUO IMMUNOASSAY MARKET BY APPLICATION

7.1. Introduction

7.2. Oncology

7.3. Blood Screening and Toxicology

7.4. Infectious Disease

7.5. Cardiology

7.6. Allergy Diagnostic

7.7. Rare and Emerging Condition Diagnostic

7.8. Others

8. UAE RUO IMMUNOASSAY MARKET BY END-USER

8.1. Introduction

8.2. Research and Academic Laboratories

8.3. Pharmaceutical and Biotechnology Companies

9. UAE RUO IMMUNOASSAY MARKET BY REGION

9.1. Introduction

9.2. Abu Dhabi

9.2.1. By Product Type

9.2.2. By Sample Type

9.2.3. By Application

9.2.4. By End-User

9.3. Dubai

9.3.1. By Product Type

9.3.2. By Sample Type

9.3.3. By Application

9.3.4. By End-User

9.4. Sharjah

9.4.1. By Product Type

9.4.2. By Sample Type

9.4.3. By Application

9.4.4. By End-User

9.5. Others

9.5.1. By Product Type

9.5.2. By Sample Type

9.5.3. By Application

9.5.4. By End-User

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. F. Hoffmann-La Roche Ltd

11.2. Merck KGaA

11.3. Danaher Corporation

11.4. Quanterix Corporation

11.5. Thermo Fisher Scientific Inc. 

11.6. GENERI BIOTECH

11.7. Becton Dickinson

12. APPENDIX

12.1. Currency 

12.2. Assumptions

12.3. Base and Forecast Years Timeline

12.4. Key benefits for the stakeholders

12.5. Research Methodology 

12.6. Abbreviations 

F. Hoffmann-La Roche Ltd

Merck KGaA

Danaher Corporation

Quanterix Corporation

Thermo Fisher Scientific Inc. 

GENERI BIOTECH

Becton Dickinson